Platform APEC
Inflammatory conditions (e.g., sepsis)
Pre-clinicalActive
Key Facts
About Regenovva
Regennova is a private, preclinical-stage biotech founded in 2015, leveraging a peptide discovery platform to develop immune-modulating therapies for inflammatory conditions like sepsis. The company's core technology involves Apolipoprotein E (ApoE) conjugates, termed APEC, aimed at rebalancing the immune response. While the pipeline remains early-stage with placeholder product descriptions, the company has secured non-dilutive grant funding from entities like the NIH and BARDA, indicating external validation of its scientific approach. Key risks include its preclinical status, undisclosed leadership, and the highly competitive landscape of immunomodulation.
View full company profile